CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07006727
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:09.329028+00:00
Published At: 2026-03-24T00:00:00+00:00
Record Updated At: 2026-03-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Small Cell Lung Carcinoma", "Large Cell Neuroendocrine Carcinoma of the Lung", "Neuroendocrine Prostate Cancer", "Gastroenteropancreatic Neuroendocrine Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-24"
protocolSection.identificationModule.nctId: "NCT07006727"
protocolSection.identificationModule.officialTitle: "A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.